The Optimal Use of Cabazitaxel for Prostate Cancer

Video

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.

Clinical Pearls

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.

  • More oncologists are becoming comfortable with using the cytotoxic chemotherapy cabazitaxel. It is only approved for use after docetaxel.
  • After prescribing docetaxel to a patient with hormone-sensitive disease, a physician can then choose to administer docetaxel again or switch to cabazitaxel.
  • Sequencing of abiraterone, enzalutamide, cabazitaxel, docetaxel, sipuleucel-T, and radium-223 is not entirely clear.
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content